induced hair loss

Hair loss caused by cytostatic drugs administered during chemotherapy, for many cancer patients has a negative influence on quality of life. Alopecia is an additional burden, not only for the patient, but also for their family and friends: Appearance is a continual reminder of the disease and its treatment, often for a significant time after completion of the chemotherapy. The hair loss is not just a cosmetic problem as the potential psychological distress ex­­ perienced by a patient cannot be un­ erestimated. d The positive impact of hair retention is a supportive element through the patients’...

The functioning of the system DigniCap™ The DigniCap™ system is a CE-certified medical product and therefore approved for application in routine clinical use within the EU and also in several other countries worldwide. Cool and control unit Scalp Cooling pre-cooling 20 – 30 min preparation/ premedication With one system 2 patients can be treated simultaneously, but independently with cooling of the scalp controlled independently via the computer interface. This cooling takes place during the entire chemotherapy session. Depending on the regime a post-cooling period of between 30 minutes and 2.5...

Clinical Evidence Sysmex has initiated a clinical trial with breast cancer patients in the biggest German Breast Center in Hamburg and in two breast centers in France. At the time of writing, more than 100 patients have been recruited for this study with good overall success rates. The majority of patients treated felt so comfortable with the outcome that they decided not to wear a wig. More scientific data on DigniCap™ system are already published (see references). In addition to data from breast cancer patients the first publications on patients with ovarian cancer, endometrial cancer, and...